Open an account

Pliant Therapeutics

PLRX · NASDAQ

$0.9124+$0.0137 (+1.52%)TodayMarket closed ·
Prev close $0.8987

About PLRX

Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2020-06-03. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Employees
49
Headquarters
South San Francisco, California
Listed
Jun 3, 2020
Sector
Health Care
Industry
Pharmaceuticals
Website
pliantrx.com

PLRX key statistics

Market cap
56.50M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
394.95K
Volume
319.69K
Open price
$0.9026
High today
$0.94
Low today
$0.8963
52 Week high
$1.95
52 Week low
$0.875

Pliant Therapeutics (PLRX) at a glance

As of Oct 20, 2026, Pliant Therapeutics (PLRX) shares are priced at $0.9124, giving the company a market cap of 56.50M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.8963 and $0.94. The current price is 1.8% above the day's low and 2.9% below its high.

Volume so far is 319.69K shares, in line with the average of 394.95K shares a day.

Over the past year Pliant Therapeutics has ranged from $0.875 to $1.95, and now sits 3% of the way up that range.

Pliant Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.36 per share against an estimate of -$0.3488.

The average analyst price target is $2.04, 123.6% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

33%of 3 analyst ratings say Buy
  • Buy33.3%
  • Hold66.7%
  • Sell0.0%
Price target · 3 analystsAvg $2.04
Low
$2.02
Now
$0.9124
High
$2.10

PLRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 11.0% on average.

  1. Q3 FY24: reported -$0.95 per share against an estimate of -$0.9886
  2. Q4 FY24: reported -$0.82 per share against an estimate of -$1.00
  3. Q1 FY25: reported -$0.92 per share against an estimate of -$0.7388
  4. Q2 FY25: reported -$0.71 per share against an estimate of -$0.7093
  5. Q3 FY25: reported -$0.43 per share against an estimate of -$0.5342
  6. Q4 FY25: reported -$0.38 per share against an estimate of -$0.3856
  7. Q1 FY26: reported -$0.32 per share against an estimate of -$0.3638
  8. Q2 FY26: reported -$0.36 per share against an estimate of -$0.3488

PLRX news

  • Press releaseGlobe Newswire

    Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

  • Press releaseGlobe Newswire

    Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board

  • Press releaseGlobe Newswire

    Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

  • Press releaseGlobe Newswire

    Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

  • Press releaseGlobe Newswire

    Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

  • Press releaseGlobe Newswire

    Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

  • Press releaseGlobe Newswire

    Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Similar companies

Companies in the same industry as Pliant Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.